2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3347 Clinical outcomes with azacitidine plus venetoclax in adult patients with relapsed or refractory acute myeloid leukemia (AML)

Aarya Murali Sr, MBBS (Hons) FRACP FRCPA, Cristiano Machado De Freitas Sr, MD2, Zahra AlHaj Issa, MD3, Aniket Bankar, MD, MSc, DM, MBBS4, Marta Davidson, PhD MD5, Maria Perusini, MD, Msc6, Dawn Maze Sr, MD7, Steven Chan, MD PhD8, Aaron Schimmer, MD PhD9, Hassan Sibai, MD, Msc, BSc10, Karen W.L. Yee Sr, MD FRCPC11, Andre C. Schuh Sr, BSc, MD, FRCPC12, Vikas Gupta, MD FRCP, FRCPath13, Guillaume Richard-Carpentier Sr, MD14
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Introduction: Azacitidine plus Venetoclax (Aza-Ven) is the standard of care for front-line treatment of AML in patients (pts) ineligible for intensive chemotherapy. Although not approved for relapsed/refractory (R/R) disease, Aza-Ven is commonly used in real-world settings for this indication. However, data on response and survival outcomes after Aza-Ven salvage is limited. Importantly, there is an unmet need to identify subgroups of pts who benefit the most from Aza-Ven in R/R AML.

Methods: We conducted a retrospective study of pts with R/R AML after intensive chemotherapy, who received Aza-Ven (with or without Gilteritinib) at Princess Margaret Cancer Centre between 2019 and 2024. Responses were categorised based on the 2022 European Leukemia Network (ELN) recommendations for AML. The primary outcome was overall survival (OS) calculated from Cycle 1 Day 1 of Aza-Ven. Composite complete remission (CRc) included CR and CR with incomplete (CRi) or partial hematological (CRh) recovery. Morphologic CR (mCR) included CRc and morphologic leukemia free state (MLFS).

Results: Our cohort included 62 pts, of whom 48% (n=30) were male. The median age at diagnosis of AML was 55 years (range 22 – 80). Aza-Ven was used in 38 (61%) pts with relapsed AML and in 24 (39%) pts with disease refractory to prior therapy. Eighteen (29%) pts had undergone an allogeneic hematopoietic stem cell transplant (HSCT) prior to receiving Aza-Ven. Twenty-nine (47%) pts had received ≥ 2 lines of therapy prior to Aza-Ven. The majority of patients received Aza-Ven alone (54/62, 87%); 8 pts received Aza-Ven-Gilt. Pts received a median of 2 cycles of Aza-Ven (range 1 – 12).

After cycle 1 of Aza-Ven-based therapy, 39% (n=24) pts achieved morphologic complete remission (mCR) (8 pts [13%] with CRc, 15 pts [24%] with MLFS; 1 pt had an external bone marrow assessment reported as mCR). Measurable residual disease (MRD) negativity by flow was achieved in 4/24 pts (17%). Among the 38 pts (61%) who did not achieve mCR after Cycle 1, 6 pts subsequently achieved mCR with continued therapy after a median of 2 cycles (range 2 – 4). Thus, the overall response rate (ORR) was 48% (n=30). Within the sub-group of 8 pts who received Aza-Ven-Gilt, the ORR was 38%. Rates of 30-day and 60-day mortality with Aza-Ven salvage were 8% and 13%, respectively. Importantly, 12/30 (40%) pts who achieved mCR, proceeded to HSCT. One pt who developed marrow aplasia after 2 cycles of Aza-Ven also proceeded to HSCT. Comparing pts who achieved mCR vs no response (NR) after Cycle 1, NPM1 mutation was significantly more common in patients achieving mCR (38% vs 8%, p=0.02). After Cycle 1, mCR was achieved in 9/13 pts (69%) with NPM1 mutation compared with 15/47 pts (32%) with NPM1 wild-type. Factors which were not significantly associated with achievement of mCR after Cycle 1 included disease status before Aza-Ven (i.e., relapsed vs refractory disease), number of prior lines of therapy (<2 vs ≥2), ELN favourable risk disease (using 2022 or 2024 criteria), TP53 mutational status or myelodysplasia related gene mutations (as defined by WHO or ICC).

The median OS in this cohort (n=62) was 7.7 months (2-year OS 22%). Median OS was 20.3 months in pts who achieved mCR after cycle 1 (2-year OS 45%) compared to 4.9 months in non-responders (2-year OS 8%) and 4.7 months in those who did not have an evaluable bone marrow at the end of cycle 1 (2-year OS 8%) (p<0.01). History of prior/concurrent malignancy (p=0.03) and KRAS mutations (p<0.01) were also associated with inferior OS. The median OS was 7.7 months in NPM1 wild-type vs 13.8 months in NPM1 mutated pts (p=0.78), but this difference was not statistically significant likely due to small patient numbers. The most prominent factor associated with improved OS was proceeding with HSCT after Aza-Ven. In pts who proceeded to HSCT, median OS was 40.4 months (2-year OS 77%) compared to 6.3 months (2-year OS 7%) in those who did not (p<0.01).

Conclusion: To the best of our knowledge, this is one of the largest real-world cohorts of R/R AML pts treated with Aza-Ven. In this study, we found that in patients achieving early blast clearance, Aza-Ven has the potential to become an effective bridge to transplant, even in the R/R setting. Furthermore, although traditional risk stratification models were not clearly prognostic in this population, specific genomic factors (such as NPM1 and KRAS mutations) may help predict response to therapy.

Aarya Murali Sr, MBBS (Hons) FRACP FRCPA: No relevant conflicts of interest to declare.